– Initial Procurement of 319,000 Treatment Courses for $115M with Additional Procurements at BARDA’s Discretion Over 10 Years –
– Emergent BioSolutions, Inc. Payment Increases to $238M Upfront and $136.5M in Potential Milestones –
DURHAM, NC, Aug. 29, 2022 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that is has signed a multi-year contract with the Biomedical Advanced Research and Development Authority (BARDA) in the US Department of Health and Human Services’ Administration for Strategic Preparedness and Response (ASPR), for the delivery of up to 1.7 million treatment courses of tablet and suspension formulations of TEBEXA® to the US government. The contract 75A50122C00047, includes an initial product procurement of 319,000 treatment courses for approximately $115 million. The 10-year contract, which contains options for future procurements, is